Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
received:
08
12
2021
revised:
03
02
2022
accepted:
11
04
2022
pubmed:
27
4
2022
medline:
9
9
2022
entrez:
26
4
2022
Statut:
ppublish
Résumé
The development of immunotherapy, in particular immune checkpoint inhibitors (ICI), has revolutionized cancer treatment in the past decades. However, its efficacy is still limited to subgroups of patients with cancer. Therefore, effective treatment combination strategies are needed. Here, radiotherapy is highly promising, as it can induce immunogenic cell death, triggering the release of pro-inflammatory cytokines, thereby creating an immunogenic phenotype and sensitizing tumors to ICI. Recently, targeted radionuclide therapy (TRT) has attained significant interest for cancer treatment. In this approach, a tumor-targeting radiopharmaceutical is used to specifically deliver a therapeutic radiation dose to all tumor cells, including distant metastatic lesions, while limiting radiation exposure to healthy tissue. However, fundamental differences between TRT and conventional radiotherapy make it impossible to directly extrapolate the biological effects from conventional radiotherapy to TRT. In this review, we present a comprehensive overview of studies investigating the immunomodulatory effects of TRT and the efficacy of combined TRT-ICI treatment. Preclinical studies have evaluated a variety of murine cancer models in which α- or β-emitting radionuclides were directed to a diverse set of targets. In addition, clinical trials are ongoing to assess safety and efficacy of combined TRT-ICI in patients with cancer. Taken together, research indicates that combining TRT and ICI might improve therapeutic response in patients with cancer. Future research has to disclose what the optimal conditions are in terms of dose and treatment schedule to maximize the efficacy of this combined approach.
Identifiants
pubmed: 35471557
pii: 708071
doi: 10.1158/1078-0432.CCR-21-4332
pmc: PMC9433955
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Radioisotopes
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3652-3657Informations de copyright
©2022 The Authors; Published by the American Association for Cancer Research.
Références
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32209603
Semin Radiat Oncol. 2020 Apr;30(2):181-186
pubmed: 32381297
Science. 2019 May 10;364(6440):558-566
pubmed: 31000591
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35190377
Cardiovasc Intervent Radiol. 2016 Jul;39(7):1076-80
pubmed: 26662290
Cancer Immunol Res. 2018 Aug;6(8):910-920
pubmed: 29907693
Nat Med. 2018 Dec;24(12):1845-1851
pubmed: 30397353
Cancers (Basel). 2021 Feb 08;13(4):
pubmed: 33567530
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
J Nucl Med. 2019 Sep;60(Suppl 2):13S-19S
pubmed: 31481583
Clin Cancer Res. 2021 Jun 1;27(11):3253-3264
pubmed: 33753455
Cancer Immunol Immunother. 2020 Oct;69(10):2075-2088
pubmed: 32447411
Nat Immunol. 2020 Feb;21(2):120-134
pubmed: 31873291
Nat Rev Cancer. 2020 Apr;20(4):203-217
pubmed: 32161398
J Nucl Med. 2018 Dec;59(12):1843-1849
pubmed: 29959213
Sci Transl Med. 2021 Jul 14;13(602):
pubmed: 34261797
Commun Biol. 2019 Feb 26;2:79
pubmed: 30820474
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
Int J Mol Sci. 2020 Nov 18;21(22):
pubmed: 33218169
J Exp Med. 2006 Apr 17;203(4):883-95
pubmed: 16606670
Oncotarget. 2016 Dec 27;7(52):86937-86947
pubmed: 27893426
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Nat Cancer. 2020 Feb;1(2):184-196
pubmed: 33768207
J Nucl Med. 2021 Feb;62(2):228-231
pubmed: 32646877
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
Front Med (Lausanne). 2015 Mar 17;2:12
pubmed: 25853132
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34615703
Cancer Immunol Immunother. 2014 Jan;63(1):1-9
pubmed: 23955682
Int J Mol Sci. 2020 Jan 24;21(3):
pubmed: 31991626
Vaccines (Basel). 2020 Oct 31;8(4):
pubmed: 33142728
Cell Death Dis. 2020 Nov 26;11(11):1013
pubmed: 33243969
ACS Pharmacol Transl Sci. 2021 Jan 26;4(1):344-351
pubmed: 33615184
Int J Mol Sci. 2021 May 03;22(9):
pubmed: 34063642
EJNMMI Radiopharm Chem. 2019 Oct 11;4(1):27
pubmed: 31659527
Nat Rev Drug Discov. 2020 Sep;19(9):589-608
pubmed: 32728208
Int J Clin Oncol. 2020 May;25(5):801-809
pubmed: 32246277
Front Cell Dev Biol. 2020 Feb 13;8:41
pubmed: 32117972
Neoplasia. 2014 Apr;16(4):319-28
pubmed: 24862758
Nat Commun. 2016 Apr 25;7:11428
pubmed: 27109210
Cell Immunol. 2021 Apr;362:104298
pubmed: 33592541
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
Curr Oncol. 2020 Apr;27(Suppl 2):S87-S97
pubmed: 32368178
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):984-994
pubmed: 33078260
Eur J Cancer. 2022 Feb;162:237-240
pubmed: 34420835
Sci Rep. 2018 Apr 3;8(1):5466
pubmed: 29615812
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Diagnostics (Basel). 2013 Oct 02;3(4):344-55
pubmed: 26824927
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70
pubmed: 14967443
J Nucl Med. 2022 Mar;63(3):396-398
pubmed: 34475234
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32616557
Clin Cancer Res. 2021 Jun 1;27(11):2970-2978
pubmed: 33419779
Crit Rev Oncol Hematol. 2017 May;113:63-70
pubmed: 28427523
Nat Commun. 2017 Nov 24;8(1):1751
pubmed: 29170499
J Endocr Soc. 2021 Aug 07;5(10):bvab133
pubmed: 34466766
Nucl Med Biol. 2021 Jul-Aug;98-99:40-58
pubmed: 34029984
Front Oncol. 2021 May 18;11:667658
pubmed: 34084750
Clin Cancer Res. 2019 Aug 1;25(15):4723-4734
pubmed: 31064781
Clin Cancer Res. 2019 Mar 15;25(6):1709-1717
pubmed: 30413527
Theranostics. 2021 Jan 1;11(1):304-315
pubmed: 33391476
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1128-35
pubmed: 21093169
Cancers (Basel). 2021 Jul 22;13(15):
pubmed: 34359580
Clin Genitourin Cancer. 2018 Apr;16(2):e469-e476
pubmed: 29137877
Theranostics. 2019 Oct 16;9(25):7948-7960
pubmed: 31695808
Theranostics. 2021 Apr 15;11(13):6120-6137
pubmed: 33995649